Navigation

In the News

Keep up to date with the latest news articles from around the world.

Articles represent the views of their authors and not ME/CFS SA. Always seek advice from a registered health practitioner before changing your care plan.

16 February, 2024

NIH To bolster RECOVER Long COVID Research Efforts Through Infusion Of $515 Million

Four years after the COVID-19 pandemic began, Long COVID remains an unsolved, complex and urgent healthcare crisis. According to the Centers for Disease Control and Prevention, 1 in 9 adults in the United States who have ever had COVID-19 continue to experience Long COVID with a wide range of symptoms. Many symptoms are debilitating, affecting patients’ ability to work and go to school. To bolster Long COVID research efforts, NIH is investing an additional $515 million over the next four years into the Researching COVID to Enhance Recovery (RECOVER) Initiative, a nationwide research program to fully understand, diagnose and treat Long COVID. Launched in 2021 with $1.15 billion in Congressional appropriations, the RECOVER Initiative is taking a systematic, comprehensive and rigorous approach to improve our understanding of Long COVID and increase the odds of identifying treatments that work.

15 February, 2024

Long COVID Patients Need Scientific Ambition, Not Defeatism

Post-viral illnesses have often been neglected by science. Insights into Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) show that this is the time to ramp up efforts.

15 February, 2024

Long COVID-19 Is Linked To Chronic Pain Conditions

Therapies for pain conditions like fibromyalgia provide clues for helping those with long COVID.

14 February, 2024

NIH Study: 5.8 Million Children And Youth Have Experienced Long COVID

A National Institutes of Health (NIH) study has found that 5.8 million children have experienced long COVID—symptoms of COVID-19 that have persisted long after the initial infection. The Nationwide research effort called the Researching COVID to Enhance Recovery (RECOVER) Initiative involved 10 pediatric hospital in the U.S., sought to provide vital information for doctors on the difficulty of diagnosing and treating post-acute sequelae of SARS-CoV-2 (PASC) and to better understanding its trajectory—and persistence—in these patients over time.

14 February, 2024

Prevalence Of Long COVID Syndrome And Its Association With Blood Group: A Cross-Sectional Study

The coronavirus disease 2019 (COVID-19) virus pandemic rapidly spread across the globe since 2020. It was characterized by a number of acute signs and symptoms. There were, however, some new-onset signs and symptoms labelled as “Long COVID”. This study was conducted to study its prevalence and associations with blood group.

13 February, 2024

Fibromyalgia, Sleep Disturbance Linked To Poor Accuracy For Divided Attention

A new study found patients with fibromyalgia had greater sleep disturbance and thus poorer accuracy for divided attention tasks than healthy controls.

13 February, 2024

Researchers Start To Find Clues On The Trail Of Long Covid

Tens of millions of people across the world are thought to suffer from long Covid, but four years after the pandemic was declared this elusive condition still cannot be tested for -- let alone treated. However research could be finally starting to find early clues on the trail of long Covid, raising hopes of future breakthroughs that may also illuminate other stubbornly ambiguous chronic syndromes.

12 February, 2024

Promising Phase 3 Trial Results of Innovative NonOpioid Painkiller for Fibromyalgia Patients

Tonix Pharmaceuticals has recently announced promising findings from a Phase 3 clinical trial conducted on TNX-102 SL, their innovative non-opioid painkiller specially developed to alleviate the symptoms of fibromyalgia. This breakthrough medication has demonstrated remarkable efficacy in reducing widespread pain, enhancing sleep quality, and mitigating fatigue among fibromyalgia patients. The trial successfully met its primary objective, paving the way for potential FDA approval in 2025. TNX-102 SL, a centrally acting analgesic, functions by improving sleep patterns, thereby providing relief from chronic pain associated with fibromyalgia.

12 February, 2024

AIM’s Ampligen Stumbles In Phase II Trial

AIM’s Ampligen failed to meet its primary endpoint in the Phase II trial in people with post-Covid fatigue.

11 February, 2024

Ivermectin Rendered Useless For COVID And Similar Viruses

Two people write in to Dr Keith Roach, MD, at US news outlet The Daily Independent Online, one about Ivermectin, and the other about ME/CFS.

Sort By

Search Articles